Landscape Capital Management L.L.C. Buys New Shares in Haemonetics Co. (NYSE:HAE)

Landscape Capital Management L.L.C. bought a new stake in shares of Haemonetics Co. (NYSE:HAE) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 32,798 shares of the medical instruments supplier’s stock, valued at approximately $3,947,000.

Other institutional investors also recently added to or reduced their stakes in the company. Quadrant Capital Group LLC raised its holdings in Haemonetics by 708.8% during the first quarter. Quadrant Capital Group LLC now owns 647 shares of the medical instruments supplier’s stock worth $54,000 after buying an additional 567 shares during the last quarter. Retirement Systems of Alabama raised its holdings in Haemonetics by 0.3% during the second quarter. Retirement Systems of Alabama now owns 66,603 shares of the medical instruments supplier’s stock worth $8,015,000 after buying an additional 205 shares during the last quarter. Jackson Square Partners LLC raised its holdings in Haemonetics by 12.8% during the first quarter. Jackson Square Partners LLC now owns 1,655,676 shares of the medical instruments supplier’s stock worth $144,838,000 after buying an additional 187,950 shares during the last quarter. Marshall Wace North America L.P. raised its holdings in Haemonetics by 181.1% during the first quarter. Marshall Wace North America L.P. now owns 6,859 shares of the medical instruments supplier’s stock worth $600,000 after buying an additional 4,419 shares during the last quarter. Finally, Oakbrook Investments LLC acquired a new position in Haemonetics during the second quarter worth $439,000. Institutional investors own 98.47% of the company’s stock.

Several research firms have weighed in on HAE. Raymond James upped their price objective on shares of Haemonetics from $110.00 to $150.00 and gave the stock an “outperform” rating in a report on Wednesday, August 7th. Morgan Stanley upped their price objective on shares of Haemonetics from $128.00 to $148.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. JMP Securities upped their price objective on shares of Haemonetics to $145.00 and gave the stock an “outperform” rating in a report on Wednesday, August 7th. Jefferies Financial Group upped their price objective on shares of Haemonetics from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Finally, TheStreet upgraded shares of Haemonetics from a “c+” rating to a “b-” rating in a report on Tuesday, May 7th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $140.67.

Shares of HAE stock traded up $0.58 on Thursday, hitting $135.38. The stock had a trading volume of 9,334 shares, compared to its average volume of 358,105. The company’s 50 day moving average is $123.70. The company has a market cap of $6.76 billion, a PE ratio of 56.64, a price-to-earnings-growth ratio of 3.26 and a beta of 0.82. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.34 and a current ratio of 2.10. Haemonetics Co. has a 12-month low of $80.24 and a 12-month high of $137.49.

Haemonetics (NYSE:HAE) last announced its earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.81 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.18. The company had revenue of $238.50 million during the quarter, compared to the consensus estimate of $236.82 million. Haemonetics had a net margin of 5.05% and a return on equity of 21.07%. The firm’s revenue for the quarter was up 4.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.59 earnings per share. As a group, equities analysts forecast that Haemonetics Co. will post 3.03 earnings per share for the current year.

In other news, CEO Christopher Simon sold 24,412 shares of the stock in a transaction dated Thursday, May 23rd. The shares were sold at an average price of $99.39, for a total value of $2,426,308.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Dan Goldstein sold 1,107 shares of the stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $103.25, for a total transaction of $114,297.75. The disclosure for this sale can be found here. In the last quarter, insiders sold 48,830 shares of company stock valued at $5,153,165. 1.32% of the stock is currently owned by corporate insiders.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Recommended Story: Percentage Gainers

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.